{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:31:41Z","timestamp":1790886701596,"version":"4.1.0"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["p-64) NCD\/Adhoc\/139\/2020-21"],"award-info":[{"award-number":["p-64) NCD\/Adhoc\/139\/2020-21"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/FST\/LS-I\/2017\/49"],"award-info":[{"award-number":["SR\/FST\/LS-I\/2017\/49"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016045","name":"University of Central Punjab","doi-asserted-by":"publisher","award":["IFD\/C\/I\/101123\/35\/04240"],"award-info":[{"award-number":["IFD\/C\/I\/101123\/35\/04240"]}],"id":[{"id":"10.13039\/100016045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jprot.2026.105598","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:54:35Z","timestamp":1767804875000},"page":"105598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Proteomic signatures in triple-negative breast cancer"],"prefix":"10.1016","volume":"325","author":[{"given":"Sohit","family":"Kashyap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Patidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aklank","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00432-010-0957-x","article-title":"Characteristics of triple-negative breast cancer","volume":"137","author":"de Ruijter","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jprot.2026.105598_bb0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch. Pathol. Lab Med."},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clbc.2025.03.006","article-title":"Harnessing artificial intelligence for precision diagnosis and treatment of triple negative breast cancer","volume":"25","author":"Hussain","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jprot.2026.105598_bb0035","first-page":"1","article-title":"Tailored therapies for triple-negative breast cancer: current landscape and future perceptions","author":"Khan","year":"2025","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0040","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/ijms26062795","article-title":"Tumor microenvironment dynamics of triple-negative breast cancer under radiation therapy","volume":"26","author":"Niture","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000498","article-title":"Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy","volume":"27","author":"Marra","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.jprot.2026.105598_bb0050","first-page":"1","article-title":"Proteomics in biomarker discovery: uncovering disease-specific interactome and post-translational modification networks","author":"Palabiyik","year":"2025","journal-title":"J. Proteins Proteomics."},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0055","first-page":"58","article-title":"Relevance of proteomics and metabolomics approaches to overview the tumorigenesis and better management of cancer","volume":"15","author":"Singh","year":"2025","journal-title":"Biotech"},{"issue":"9","key":"10.1016\/j.jprot.2026.105598_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110460","article-title":"Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer","volume":"38","author":"Gong","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0065","first-page":"23","article-title":"Data-independent acquisition (DIA) mass spectrometry reveals related proteins involved in the occurrence of early intestinal-type gastric cancer","volume":"41","author":"Zhang","year":"2023"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0070","article-title":"Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics","volume":"12","author":"G\u00e1mez-Pozo","year":"2017"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0075","first-page":"110","article-title":"Comparative profiling of triple-negative breast carcinomas tissue glycoproteome by sequential purification of glycoproteins and stable isotope labeling","volume":"38","author":"Chen","year":"2016"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0080","first-page":"61","article-title":"The Analyzer Forms the Most Important Component of the Instrument and is Responsible for Separation of, Module II-Mass","volume":"5","author":"Gollapalli","year":"2014","journal-title":"Spectrometry"},{"issue":"4","key":"10.1016\/j.jprot.2026.105598_bb0085","article-title":"Parallel analyses by mass spectrometry (MS) and reverse phase protein Array (RPPA) reveal complementary proteomic profiles in triple-negative breast cancer (TNBC) patient tissues and cell cultures","volume":"25","author":"Wang","year":"2025"},{"key":"10.1016\/j.jprot.2026.105598_bb0090","series-title":"Spatial Transcriptomic and Proteomic Insight into Trop-2, HER2, and AR Expression: A Pathway to Tailored Therapies in Triple-Negative Breast cancer","author":"Carausu","year":"2024"},{"issue":"3\u20134","key":"10.1016\/j.jprot.2026.105598_bb0095","first-page":"283","article-title":"Shotgun proteomics of archival triple-negative breast cancer samples","volume":"7","author":"G\u00e1mez-Pozo","year":"2013"},{"issue":"10","key":"10.1016\/j.jprot.2026.105598_bb0100","first-page":"5034","article-title":"Mass spectrometry (LC\u2013MS\/MS) identified proteomic biosignatures of breast cancer in proximal fluid","volume":"11","author":"Whelan","year":"2012"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1039\/C6MB00639F","article-title":"Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer","volume":"13","author":"Miah","year":"2017","journal-title":"Mol. BioSyst."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202400101","article-title":"Advancements in single-cell proteomics and mass spectrometry-based techniques for unmasking cellular diversity in triple negative breast cancer","volume":"19","author":"Nalla","year":"2025","journal-title":"PROTEOMICS Clin. Appl."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12885-020-6668-z","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41698-025-00907-8","article-title":"Quantitative proteomics analysis of triple-negative breast cancers","volume":"9","author":"Mariano","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.jprot.2026.105598_bb0125","first-page":"51","article-title":"The diagnostic value of serum tumor markers CEA, CA19\u20139, CA125, CA15\u20133, and TPS in metastatic breast cancer","volume":"470","author":"Wang","year":"2017"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0130","first-page":"342","article-title":"A review of biosensors for detecting tumor markers in breast cancer","volume":"12","author":"Hong","year":"2022"},{"key":"10.1016\/j.jprot.2026.105598_bb0135","first-page":"v46","article-title":"Evaluation and diagnostic potential of plasma biomarkers in bladder cancer","volume":"30","author":"Voronova","year":"2019"},{"key":"10.1016\/j.jprot.2026.105598_bb0140","article-title":"Strategies for five tumour markers in the screening and diagnosis of female breast cancer","volume":"12","author":"Luo","year":"2023"},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0145","first-page":"3219","article-title":"Correlation of CA125, CA153, and CEA levels in the diagnosis and prognosis of triple-negative breast cancer","volume":"13","author":"Lou","year":"2020"},{"issue":"9","key":"10.1016\/j.jprot.2026.105598_bb0150","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jpm14090944","article-title":"Mass spectrometry-based proteomics for classification and treatment optimisation of triple negative breast cancer","volume":"14","author":"Metwali","year":"2024","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227404","article-title":"Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer","volume":"15","author":"Al-Wajeeh","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178296","article-title":"Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics","volume":"12","author":"G\u00e1mez-Pozo","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0165","first-page":"631","article-title":"CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients","volume":"144","author":"Pedersen","year":"2019"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0170","article-title":"Extracellular vesicle proteome analysis improves diagnosis of recurrence in triple-negative breast cancer","volume":"14","author":"Hyon","year":"2025"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0175","first-page":"37","article-title":"Extracellular matrix 1 (ECM1) regulates the actin cytoskeletal architecture of aggressive breast cancer cells in part via S100A4 and Rho-family GTPases","volume":"34","author":"G\u00f3mez-Contreras","year":"2017"},{"issue":"6_Supplement","key":"10.1016\/j.jprot.2026.105598_bb0180","first-page":"1843","article-title":"Integrating machine learning with microfluidic technologies for proteomic profiling of extracellular vesicles in triple-negative breast cancer","volume":"84","author":"Kim","year":"2024"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0185","first-page":"1016","article-title":"Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells","volume":"48","author":"Fang","year":"2016"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100703","article-title":"Proteomic analysis revealed the potential role of MAGE-D2 in the therapeutic targeting of triple-negative breast cancer","volume":"23","author":"Shi","year":"2024","journal-title":"Mol Cell Proteomics."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0195","first-page":"52","article-title":"Quantitative proteomics reveals serum proteome alterations during metastatic disease progression in breast cancer patients","volume":"21","author":"Kaur","year":"2024"},{"issue":"25","key":"10.1016\/j.jprot.2026.105598_bb0200","first-page":"2651","article-title":"Antibody\u2013drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018"},{"key":"10.1016\/j.jprot.2026.105598_bb0205","series-title":"Antibody\u2013drug Conjugates: A New Therapeutic Approach for Triple-negative Breast Cancer","first-page":"1","author":"Al Jarroudi","year":"2024"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0210","first-page":"489","article-title":"Identification of GPNMB in endometrial cancer based on pan-cancer analysis and in vitro validation","volume":"15","author":"Tuo","year":"2024"},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0215","article-title":"Prognostic value of Trop-2 expression in nonmetastatic triple-negative breast cancer and correlation with emerging","volume":"14","author":"Jacot","year":"2025","journal-title":"Biomarkers"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0220","first-page":"817","article-title":"Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities","volume":"45","author":"Tiwari","year":"2025"},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0225","first-page":"801","article-title":"Overexpression of MUC1 predicts poor prognosis in patients with breast cancer","volume":"41","author":"Jing","year":"2019"},{"issue":"11","key":"10.1016\/j.jprot.2026.105598_bb0230","first-page":"4132","article-title":"Zinc transporter LIV1: a promising cell surface target for triple negative breast cancer","volume":"237","author":"Saravanan","year":"2022"},{"issue":"2\u20133","key":"10.1016\/j.jprot.2026.105598_bb0235","first-page":"154","article-title":"Combined detection of CK5\/6, CK14 and EGFR in diagnosis of basal-like subtype triple negative breast cancer","volume":"8","author":"Li","year":"2020","journal-title":"Med. J. Peking Union Med. Coll. Hosp."},{"key":"10.1016\/j.jprot.2026.105598_bb0240","series-title":"Potential Clinically Useful Prognostic Biomarkers in Triple-negative Breast Cancer: Preliminary Results of a Retrospective Analysis","first-page":"177","author":"Ilie","year":"2018"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0245","first-page":"18","article-title":"Triple-negative breast cancer is associated with EGFR, CK5\/6 and c-KIT expression in Malaysian women","volume":"12","author":"Kanapathy Pillai","year":"2012"},{"key":"10.1016\/j.jprot.2026.105598_bb0250","first-page":"43","article-title":"Prognostic impact of EGFR and cytokeratin 5\/6 immunohistochemical expression in triple-negative breast cancer","volume":"28","author":"Abdelrahman","year":"2017"},{"key":"10.1016\/j.jprot.2026.105598_bb0255","series-title":"The Expressions of NEDD9 and E-cadherin Correlate with Metastasis and Poor Prognosis in Triple-negative Breast Cancer Patients","first-page":"5751","author":"Li","year":"2016"},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0260","first-page":"603","article-title":"Prognostic value of E-cadherin and \u03b2-catenin in triple-negative breast cancer","volume":"146","author":"Shen","year":"2016"},{"issue":"44","key":"10.1016\/j.jprot.2026.105598_bb0265","first-page":"76974","article-title":"The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5\/6 expression in patients with triple negative breast cancer","volume":"8","author":"Adamo","year":"2017"},{"issue":"10","key":"10.1016\/j.jprot.2026.105598_bb0270","first-page":"2159","article-title":"MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer","volume":"44","author":"Siroy","year":"2013"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0275","first-page":"195","article-title":"Tissue and serum MUC1 mucin detection in breast cancer patients","volume":"81","author":"Croce","year":"2003"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0280","first-page":"81","article-title":"Trop-2-cells, their Exosomal cargo, and the potential impact on diagnostics and therapeutics in breast cancer: the expanding","volume":"8","author":"Kok","year":"2023","journal-title":"Frontiers"},{"key":"10.1016\/j.jprot.2026.105598_bb0285","article-title":"Detection of MUC1 protein on tumor cells and their derived exosomes for breast cancer surveillance with an electrochemiluminescence aptasensor","volume":"882","author":"Li","year":"2021"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0290","article-title":"The role of glycoprotein non-metastatic melanoma Protein B (GPNMB) in tumors and other diseases","volume":"4","author":"Wu","year":"2025"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0295","first-page":"6276","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0300","first-page":"62","article-title":"Triple negative breast cancer: a review of present and future diagnostic modalities","volume":"57","author":"Dass","year":"2021"},{"issue":"11","key":"10.1016\/j.jprot.2026.105598_bb0305","first-page":"2243","article-title":"Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications","volume":"75","author":"G\u00e1mez-Pozo","year":"2015"},{"key":"10.1016\/j.jprot.2026.105598_bb0310","first-page":"1152","article-title":"Identification of apolipoprotein CI peptides as a potential biomarker and its biological roles in breast cancer","volume":"22","author":"Sun","year":"2016"},{"issue":"16","key":"10.1016\/j.jprot.2026.105598_bb0315","first-page":"380","article-title":"Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer","volume":"7","author":"Yi","year":"2019"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0320","first-page":"635","article-title":"Diagnostic and prognostic significance of serum apolipoprotein CI in triple-negative breast cancer based on mass spectrometry","volume":"17","author":"Song","year":"2016"},{"issue":"17","key":"10.1016\/j.jprot.2026.105598_bb0325","first-page":"29487","article-title":"Fatty acid metabolism in breast cancer subtypes","volume":"8","author":"Monaco","year":"2017"},{"key":"10.1016\/j.jprot.2026.105598_bb0330","first-page":"30137","article-title":"SBFI-26 enhances apoptosis in docetaxel-treated triple-negative breast cancer cells by increasing ROS levels","volume":"15","author":"He","year":"2024","journal-title":"BioImpacts"},{"issue":"10","key":"10.1016\/j.jprot.2026.105598_bb0335","article-title":"USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer","volume":"38","author":"Su","year":"2024"},{"key":"10.1016\/j.jprot.2026.105598_bb0340","series-title":"Identification of TBC1D7 as a Metabolic Prognostic Biomarker in Breast Cancer","author":"Lupi","year":"2025"},{"issue":"9","key":"10.1016\/j.jprot.2026.105598_bb0345","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41419-024-07037-2","article-title":"TBC1 domain-containing proteins are frequently involved in triple-negative breast cancers in connection with the induction of a glycolytic phenotype","volume":"15","author":"Lupi","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0350","first-page":"96","article-title":"Mitochondrial ribosomal proteins and cancer","volume":"61","author":"Wu","year":"2025"},{"issue":"8","key":"10.1016\/j.jprot.2026.105598_bb0355","first-page":"308","article-title":"High glycolytic activity signature reveals CCNB2 as a key therapeutic target in triple-negative","volume":"29","author":"Liang","year":"2024","journal-title":"Breast Cancer."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0360","first-page":"357","article-title":"Expression profiles of FABP4 and FABP5 in breast cancer: clinical implications and perspectives","volume":"16","author":"Jiang","year":"2025"},{"key":"10.1016\/j.jprot.2026.105598_bb0365","series-title":"GD3 Synthase Drives Resistance to p53-induced Apoptosis in Breast Cancer by Modulating Mitochondrial Function","first-page":"1","author":"Anand","year":"2025"},{"key":"10.1016\/j.jprot.2026.105598_bb0370","article-title":"Mitochondrial ribosomal proteins: potential targets for cancer prognosis and therapy","volume":"15","author":"Zhu","year":"2025"},{"key":"10.1016\/j.jprot.2026.105598_bb0375","first-page":"274","article-title":"Role of extracellular matrix in breast cancer development: a brief update","volume":"7","author":"Jena","year":"2018"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107347","article-title":"Extracellular proteolysis in cancer: proteases, substrates, and mechanisms in tumor progression and metastasis","volume":"300","author":"Radisky","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0385","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/ijms24032100","article-title":"Proteins found in the triple-negative breast cancer secretome and their therapeutic potential","volume":"24","author":"McHenry","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jprot.2026.105598_bb0390","first-page":"1517","article-title":"A pair of prognostic biomarkers in triple-negative breast cancer: KLK10 and KLK11 mRNA expression","volume":"12","author":"Liu","year":"2022"},{"issue":"25","key":"10.1016\/j.jprot.2026.105598_bb0395","doi-asserted-by":"crossref","first-page":"17876","DOI":"10.18632\/oncotarget.24947","article-title":"Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types","volume":"9","author":"Tailor","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0400","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bjc.6601451","article-title":"Kallikrein gene downregulation in breast cancer","volume":"90","author":"Yousef","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0405","first-page":"17","article-title":"Relationship between matrix metalloproteinase-9 and some clinicopathological prognostic factors of breast carcinoma","volume":"10","author":"Mohammadizadeh","year":"2021","journal-title":"Am. J. Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0410","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12885-021-07860-2","article-title":"Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis","volume":"21","author":"Jiang","year":"2021","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.jprot.2026.105598_bb0415","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.18632\/oncotarget.1932","article-title":"Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer","volume":"5","author":"Mehner","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0420","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/ol.2020.12339","article-title":"Prognostic role of matrix metalloproteinase 9 in early breast cancer","volume":"21","author":"Kalavska","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jprot.2026.105598_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.842898","article-title":"Extracellular vesicles: the landscape in the progression, diagnosis, and treatment of triple-negative breast cancer","volume":"10","author":"Dong","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"22","key":"10.1016\/j.jprot.2026.105598_bb0430","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.3390\/ijms232213993","article-title":"Tumor-derived exosomes and their role in breast cancer metastasis","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.jprot.2026.105598_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202300062","article-title":"Extracellular vesicle proteins as breast cancer biomarkers: mass spectrometry-based analysis","volume":"24","author":"Bandu","year":"2024","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2026.105598_bb0440","article-title":"Construction and validation of a prognostic risk model for triple-negative breast cancer based on autophagy-related genes","volume":"12","author":"Yan","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0445","first-page":"20191","article-title":"Genetic evidence supporting potential causal roles of EIF4 family in breast cancer: a two-sample randomized Mendelian study","volume":"14","author":"Shi","year":"2024"},{"key":"10.1016\/j.jprot.2026.105598_bb0450","first-page":"9","article-title":"17P tripartite motif containing 2: S glutamine metabolism-associated protein, predicts poor patient outcome in triple-negative breast cancer treated with chemotherapy","author":"Masisi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jprot.2026.105598_bb0455","series-title":"Investigation of the Neddylation Pathway in Triple Negative Breast Cancer","author":"Alford","year":"2023"},{"issue":"12","key":"10.1016\/j.jprot.2026.105598_bb0460","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1111\/cas.16356","article-title":"SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA","volume":"115","author":"Yu","year":"2024","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jprot.2026.105598_bb0465","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2147\/IJGM.S462541","article-title":"SEPT3 as a potential molecular target of triple-negative breast cancer","author":"Yang","year":"2024","journal-title":"Int. J. Gen. Med."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0470","first-page":"21786","article-title":"Combined knockdown of CD151 and MMP9 may inhibit the malignant biological behaviours of triple-negative breast cancer through the GSK-3\u03b2\/\u03b2-catenin-related pathway","volume":"14","author":"Li","year":"2024"},{"key":"10.1016\/j.jprot.2026.105598_bb0475","article-title":"Proteomic landscape of exosomes reveals the functional contributions of CD151 in triple-negative breast cancer","volume":"20","author":"Li","year":"2021"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0480","first-page":"110","article-title":"The controversial role of CD151 in different solid tumors: promoter or suppressor?","volume":"25","author":"Gao","year":"2025"},{"key":"10.1016\/j.jprot.2026.105598_bb0485","series-title":"CD151 Promotes Cancer Progression in Triple-Negative Breast Cancer by Inducing EMT through the MAPK Signaling Pathway","first-page":"455","author":"Lv","year":"2025"},{"issue":"32","key":"10.1016\/j.jprot.2026.105598_bb0490","first-page":"3778","article-title":"A network-based cancer drug discovery: from integrated multi-omics approaches to precision medicine","volume":"24","author":"Turanli","year":"2018"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0495","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41597-022-01512-1","article-title":"Proteomic characterisation of triple negative breast cancer cells following CDK4\/6 inhibition","volume":"9","author":"Beykou","year":"2022","journal-title":"Sci. Data"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0500","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.jprot.2026.105598_bb0505","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/1078-0432.CCR-14-2023","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor\u2013treated melanoma patients","volume":"21","author":"Kakavand","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0510","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jprot.2026.105598_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156590","article-title":"Expression and function of cytokine interleukin-22 gene in the tumor microenvironment of triple negative breast cancer","volume":"179","author":"Xiao","year":"2024","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.jprot.2026.105598_bb0520","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/cimb47070537","article-title":"Serum levels of IL-21 and IL-22 in breast cancer patients\u2014a preliminary study","volume":"47","author":"Kabut","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.jprot.2026.105598_bb0525","series-title":"Therapeutic Targeting of the IL-22\/IL-22R\u03b1 Axis in Ovarian Cancer: A Novel Approach to Suppressing Tumor Proliferation","author":"\uc548\ud6a8\ube48","year":"2025"},{"key":"10.1016\/j.jprot.2026.105598_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1499950","article-title":"Unlocking the epigenetic code: new insights into triple-negative breast cancer","volume":"14","author":"Mahendran","year":"2024","journal-title":"Front. Oncol."},{"issue":"13","key":"10.1016\/j.jprot.2026.105598_bb0535","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk4423","article-title":"Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT: AP-1 signaling","volume":"10","author":"Chomiak","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jprot.2026.105598_bb0540","article-title":"Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform!","volume":"279","author":"Guadagni","year":"2024"},{"key":"10.1016\/j.jprot.2026.105598_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177001","article-title":"Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy","volume":"983","author":"Ramadan","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0550","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41420-024-01895-7","article-title":"Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer","volume":"10","author":"Huang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0555","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jprot.2026.105598_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0565","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0570","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.jprot.2026.105598_bb0575","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase 1 olaparib and radiation therapy for triple-negative breast cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0580","doi-asserted-by":"crossref","first-page":"10956","DOI":"10.1038\/s41598-021-90527-6","article-title":"HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation","volume":"11","author":"Alothaim","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0585","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhep.2022.02.007","article-title":"Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models","volume":"77","author":"Olaizola","year":"2022","journal-title":"J. Hepatol."},{"issue":"47","key":"10.1016\/j.jprot.2026.105598_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202511789","article-title":"Cancer biology of GSPT1: mechanisms and targeted therapy opportunities of molecular glue degraders","volume":"12","author":"Lin","year":"2025","journal-title":"Adv. Sci."},{"issue":"12_Supplement","key":"10.1016\/j.jprot.2026.105598_bb0595","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P4-12-23","article-title":"Abstract P4-12-23: Z-Endoxifen-PROTAC, a novel drug for chemo-sensitive and-resistant triple negative breast cancer","volume":"31","author":"Jayaraman","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0600","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.7150\/ijbs.94058","article-title":"Dysregulated ribosome biogenesis is a targetable vulnerability in triple-negative breast cancer: MRPS27 as a key mediator of the stemness-inhibitory effect of lovastatin","volume":"20","author":"Zheng","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0605","first-page":"155","article-title":"Design, screening and development of asymmetric siRNAs targeting the MYC oncogene in triple-negative","volume":"33","author":"Mekonnen","year":"2024","journal-title":"Breast Cancer."},{"issue":"4","key":"10.1016\/j.jprot.2026.105598_bb0610","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2174\/1574892816666211130170149","article-title":"Prognostic and therapeutic values of autophagy-related genes in triple-negative breast cancer","volume":"17","author":"Liu","year":"2022","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0615","first-page":"90","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0620","first-page":"345","article-title":"Harmonizing PD-L1 testing in metastatic triple negative breast cancer","volume":"22","author":"Giugliano","year":"2022"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0625","first-page":"25","article-title":"Tumor-infiltrating lymphocyctes in triple-negative breast cancer: update for 2020","volume":"27","author":"Brown","year":"2021"},{"issue":"28","key":"10.1016\/j.jprot.2026.105598_bb0630","first-page":"44288","article-title":"Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: a meta-analysis","volume":"7","author":"Wang","year":"2016"},{"key":"10.1016\/j.jprot.2026.105598_bb0635","series-title":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","article-title":"The evolution of triple-negative breast cancer: from biology to novel therapeutics","author":"Anders","year":"2016"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0640","first-page":"1","article-title":"Clinical trials of immunotherapy in triple-negative breast cancer","volume":"195","author":"Howard","year":"2022"},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0645","first-page":"664","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130","volume":"114","author":"Badve","year":"2022"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0650","first-page":"986","article-title":"High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers","volume":"15","author":"Jacot","year":"2015"},{"key":"10.1016\/j.jprot.2026.105598_bb0655","series-title":"Epidermal Growth Factor Receptor (EGFR) Gene Alteration and Protein Overexpression in Malaysian Triple-negative Breast Cancer (TNBC) Cohort","first-page":"7749","author":"Zakaria","year":"2019"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0660","first-page":"1","article-title":"Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters","volume":"2","author":"Hashmi","year":"2019"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0665","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5306\/wjco.v6.i6.252","article-title":"Biomarkers in triple negative breast cancer: a review","volume":"6","author":"Yadav","year":"2015","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0670","first-page":"225","article-title":"The prognostic and predictive potential of Ki-67 in triple-negative breast cancer","volume":"10","author":"Zhu","year":"2020"},{"issue":"34","key":"10.1016\/j.jprot.2026.105598_bb0675","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1200\/JCO.2012.42.6858","article-title":"Publication of tumor marker research results: the necessity for complete and transparent reporting","volume":"30","author":"McShane","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.jprot.2026.105598_bb0680","first-page":"31079","article-title":"Prognostic and predictive value of Ki-67 in triple-negative breast cancer","volume":"7","author":"Wang","year":"2016"},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0685","first-page":"1100","article-title":"High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer","volume":"108","author":"Zagouri","year":"2013"},{"key":"10.1016\/j.jprot.2026.105598_bb0690","article-title":"MET and FASN as prognostic biomarkers of triple negative breast cancer: a systematic evidence landscape of clinical study","volume":"11","author":"Jiang","year":"2021"},{"issue":"43","key":"10.1016\/j.jprot.2026.105598_bb0695","first-page":"74391","article-title":"Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer","volume":"8","author":"Gir\u00f3-Perafita","year":"2017"},{"issue":"2_Supplement","key":"10.1016\/j.jprot.2026.105598_bb0700","first-page":"1082","article-title":"Expression of fatty acid synthase as a prognostic marker in triple negative breast cancer","volume":"69","author":"Kang","year":"2009"},{"issue":"14","key":"10.1016\/j.jprot.2026.105598_bb0705","article-title":"Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)","volume":"96","author":"Ma","year":"2017"},{"key":"10.1016\/j.jprot.2026.105598_bb0710","article-title":"The prognostic value of stem cell markers in triple-negative breast cancer","volume":"29","author":"Alm\u00e1si","year":"2023"},{"issue":"1","key":"10.1016\/j.jprot.2026.105598_bb0715","article-title":"ALDH1 cancer stem cell marker as a prognostic factor in triple-negative breast cancer","volume":"2020","author":"Panigoro","year":"2020"},{"issue":"4_Supplement","key":"10.1016\/j.jprot.2026.105598_bb0720","article-title":"Abstract P2\u201308-33: A novel seven-gene signature predicts prognosis in early-stage triple-negative breast cancer","volume":"79","author":"Ren","year":"2019"},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0725","first-page":"319","article-title":"The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target","volume":"193","author":"Yang","year":"2022"},{"issue":"11","key":"10.1016\/j.jprot.2026.105598_bb0730","first-page":"2044","article-title":"The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I\u2013III triple-negative breast cancer","volume":"128","author":"Sun","year":"2023"},{"issue":"2","key":"10.1016\/j.jprot.2026.105598_bb0735","first-page":"566","article-title":"Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer","volume":"77","author":"Wali","year":"2017"},{"issue":"11","key":"10.1016\/j.jprot.2026.105598_bb0740","first-page":"674","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016"},{"issue":"5","key":"10.1016\/j.jprot.2026.105598_bb0745","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae041","article-title":"Estradiol induces bone osteolysis in triple\u2013negative breast cancer via its membrane\u2013associated receptor ER\u03b136","volume":"8","author":"Cohen","year":"2024","journal-title":"JBMR Plus"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0750","doi-asserted-by":"crossref","first-page":"205","DOI":"10.21037\/atm-20-5989","article-title":"Identification of novel prognostic genes of triple-negative breast cancer using meta-analysis and weighted gene co-expressed network analysis","volume":"9","author":"Cao","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.jprot.2026.105598_bb0755","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0760","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/jcm12030953","article-title":"Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges","volume":"12","author":"Wang","year":"2023","journal-title":"J. Clin. Med."},{"issue":"7605","key":"10.1016\/j.jprot.2026.105598_bb0765","first-page":"55","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016"},{"issue":"3","key":"10.1016\/j.jprot.2026.105598_bb0770","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/cancers16030516","article-title":"Integrated proteogenomic analysis reveals distinct potentially actionable therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"16","author":"Kaur","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.jprot.2026.105598_bb0775","first-page":"2367","article-title":"Triple negative breast cancer detection using LC\u2013MS\/MS lipidomic profiling","volume":"19","author":"Eghlimi","year":"2020"},{"issue":"10","key":"10.1016\/j.jprot.2026.105598_bb0780","first-page":"1563","article-title":"RB1 and p53 at the crossroad of EMT and triple-negative breast cancer","volume":"10","author":"Jiang","year":"2011"},{"issue":"10","key":"10.1016\/j.jprot.2026.105598_bb0785","first-page":"3739","article-title":"RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation","volume":"126","author":"Jones","year":"2016"},{"issue":"12","key":"10.1016\/j.jprot.2026.105598_bb0790","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70023","article-title":"Multimodal data fusion AI model uncovers tumor microenvironment immunotyping heterogeneity and enhanced risk stratification of breast cancer","volume":"5","author":"Yu","year":"2024","journal-title":"MedComm"}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391926000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391926000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T20:01:47Z","timestamp":1769889707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391926000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":158,"alternative-id":["S1874391926000011"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2026.105598","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic signatures in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2026.105598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105598"}}